Breaking News

Primmune Selects SARS-CoV-2 Clinical Candidate

Demonstrates sustained dose-dependent innate immune induction in vivo without the production of inflammatory cytokines.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Primmune Therapeutics has selected PRTX007 as its lead clinical development candidate for SARS-CoV-2 (the virus that causes COVID-19) and for oncology indications. “PRTX007 is an oral small molecule that specifically activates toll-like receptor 7 (“TLR7″) which drives the innate immune system’s primary response to viral infections,” said James Appleman, Ph.D., Co-founder and Chief Scientific Officer at Primmune Therapeutics. “PRTX007 was derived from Primm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters